Compare GRDN & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRDN | PRCT |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2024 | 2021 |
| Metric | GRDN | PRCT |
|---|---|---|
| Price | $29.35 | $35.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $32.00 | ★ $56.57 |
| AVG Volume (30 Days) | 351.5K | ★ 1.6M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,389,638,000.00 | $299,907,000.00 |
| Revenue This Year | $19.50 | $48.34 |
| Revenue Next Year | $0.48 | $29.35 |
| P/E Ratio | $105.18 | ★ N/A |
| Revenue Growth | 18.68 | ★ 50.07 |
| 52 Week Low | $17.78 | $27.80 |
| 52 Week High | $37.43 | $99.60 |
| Indicator | GRDN | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.79 | 62.39 |
| Support Level | $28.62 | $29.04 |
| Resistance Level | $29.90 | $32.93 |
| Average True Range (ATR) | 1.04 | 1.63 |
| MACD | -0.06 | 0.67 |
| Stochastic Oscillator | 62.26 | 96.29 |
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.